바이오라인 RX(ADR) (BLRX) 주가

바이오라인 RX(ADR)(BLRX)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.49 (+2.05%), 시가총액 $12.87M, 52주 범위 $2.18 ~ $5.93.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd.

핵심 지표

• 현재가: $2.49 (+2.05%)
• 시가총액: $12.87M
• 52주 최저~최고: $2.18 ~ $5.93
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

바이오라인 RX(ADR)의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

바이오라인 RX(ADR) 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.5 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.68
• 순이익률: -99.58%

자주 묻는 질문